Companies/C21 Investments Inc.

Company profile

C21 Investments Inc.

OTC: CXXIF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Vancouver, BCCIK 0000831609Reports USD

#485 of 1,394 Healthcare companies by revenue54th-percentile growth

EA Score

48D

FH 71DQ 17GM 41SS 53

v0.1 · 65/100 weight · provisional

↑ operating margin, Piotroski F · ↓ filing timeliness, growth stability

Methodology →

Revenue TTM

$32.6M

Rev growth YoY (TTM)

+8.4%

Net income (FY)

-$3.2M

Employees

114

Market cap

$29.0M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$32.6M$32.6M2026

Net income-$3.2M-$3.2M2026

Operating income$2.3M$2.3M2026

Total assets$54.4M$54.4M2026

Liabilities$29.0M$29.0M2026

Equity$25.4M$25.4M2026

Revenue trend

FY2022 – FY2026 · USD

$33.5M

FY22

$33.0M

FY22

$28.9M

FY23

$28.3M

FY24

$4.5M

FY24

$30.1M

FY25

$32.6M

FY26

Revenue by segment

Filed disclosures · FY2024

By product

Consolidated100%

Corporate0%

By geography

Nevada100%

The read

C21 Investments Inc. booked $32.6M in FY2026 revenue, growing 8.3% year over year — about the middle of the pack among Healthcare companies we track, at a -9.9% net margin.

Peers · Healthcare

Provectus Biopharmaceuticals, Inc.36D Sangamo Therapeutics, Inc.——NurExone Biologic Inc.——Bioqual, Inc.65B

Key facts

CEOSonny Newman

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersVancouver, BC

ExchangeOTC: CXXIF

Employees114

IPO date2018-06-22

Latest filings

6-K2026-07-09 6-K2026-06-22 6-K2026-06-15 6-K2026-06-12 20-F2026-06-12 6-K2026-02-10 6-K2026-02-10 6-K2025-11-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.